Revotar is a biopharmaceutical company developing small molecule anti-inflammatory drugs for indications such as asthma, psoriasis, ALI/ARDS and COPD. The company was endowed from the start with the asset bimosiamose, an innovative proprietary drug product (selectin antagonist) for the therapy of a variety of inflammatory disorders. Its advanced drug candidate bimosiamose has passed three Phase II a (proof of concept) clinical trials in Asthma and Psoriasis.
